Mundipharma-International

Médias

New Results add to Growing Body of Evidence That Support Bendamustine-rituximab (B-R) Combination as First-Line Treatment in Patients With Indolent non-Hodgkin (iNHL) and Mantle Cell Lymphomas (MCL)

Médias

Record Number of Bendamustine Abstracts Accepted for Presentation at the Annual Meeting of the American Society of Hematology (ASH)